Last reviewed 2026-05-14 · How we verify

ertugliflozine

Amsterdam UMC, location VUmc · FDA-approved active Small molecule Quality 1/100

ertugliflozine is a Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently FDA-approved.

At a glance

Generic name	ertugliflozine
Sponsor	Amsterdam UMC, location VUmc
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ertugliflozine CI brief — competitive landscape report
ertugliflozine updates RSS · CI watch RSS
Amsterdam UMC, location VUmc portfolio CI

Frequently asked questions about ertugliflozine

What is ertugliflozine?

ertugliflozine is a Small molecule drug developed by Amsterdam UMC, location VUmc.

Who makes ertugliflozine?

ertugliflozine is developed and marketed by Amsterdam UMC, location VUmc (see full Amsterdam UMC, location VUmc pipeline at /company/amsterdam-umc-location-vumc).

What development phase is ertugliflozine in?

ertugliflozine is FDA-approved (marketed).

Manufacturer: Amsterdam UMC, location VUmc — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing